Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
(Queen Mary University of London, University of Cambridge, University College London, NHS Blood and Transplant) and international sites (including VU Amsterdam, KU Leuvan, MRC Gambia, Apollo Hospitals
-
co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and
-
node), Imperial College London, Queen Mary University of London, Durham University, and the University of Aberdeen - https://www.cs.ox.ac.uk/projects/AIHub/ . The programme offers an excellent
-
node), Imperial College London, Queen Mary University of London, Durham University, and the University of Aberdeen - https://www.cs.ox.ac.uk/projects/AIHub/ . The programme offers an excellent
-
techniques will be used, including Large Language Models (LLMs). About Queen Mary At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable
-
-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and improving
-
Evaluation The evaluation panel consists of the following effective members: Doctor Cláudia Nunes dos Santos, NIMSB (panel coordinator); Doctor Inês Sequeira, Queen Mary University of London; Doctor Sophia
-
co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and
-
-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and improving
-
– a £43.6M national programme co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing